Carcinoma In Situ (CIS): Definition

Print this article

Carcinoma in situ (CIS) is an early form of cancer in which abnormal cells are confined to the epithelium, the layer of tissue where they first developed, and have not yet spread into the surrounding tissue. “In situ” is Latin for “in its original place.” Because the cells have not broken through the basement membrane — the thin structural boundary beneath the epithelium — they cannot access blood vessels or lymphatic channels and therefore cannot spread to other parts of the body. This makes carcinoma in situ one of the most treatable forms of cancer, and complete removal is usually curative. If left untreated, carcinoma in situ can progress over time to become invasive carcinoma, in which cancer cells break through into the deeper tissue and gain the ability to spread.

What does carcinoma in situ look like under the microscope?

When a pathologist examines carcinoma in situ, the abnormal cells show features of malignancy — enlarged, irregular nuclei, abnormal cell division, and loss of the normal, organized arrangement of the epithelium. The critical finding that defines CIS is that these malignant cells remain entirely within the epithelial layer. The underlying basement membrane is intact, confirming that no invasion has occurred. In some locations, the pathologist may use special stains or immunohistochemistry (IHC) to confirm that the basement membrane is preserved.

How is carcinoma in situ different from invasive carcinoma?

The distinction between in situ and invasive is one of the most important in all of pathology — it directly determines the risk of spread and the treatment approach:

Carcinoma in situ — abnormal cells are confined to the epithelium and cannot spread to lymph nodes or distant organs. Treatment is focused on completely removing the abnormal tissue. The outlook is excellent when the lesion is fully excised.
Invasive carcinoma — cancer cells have broken through the basement membrane and entered the surrounding tissue. They can access blood vessels and lymphatics, creating the potential for spread. Treatment is usually more extensive and may involve surgery, radiation, chemotherapy, or targeted therapy, depending on the cancer type and stage.

Finding carcinoma in situ near an invasive tumor in the same specimen is common — it often represents the precursor lesion from which the invasive cancer developed.

What are the most common types of carcinoma in situ?

Carcinoma in situ can develop in any organ that contains epithelial cells. The most commonly encountered types are:

Ductal carcinoma in situ (DCIS) — a non-invasive breast cancer confined to the milk ducts. It is the most common form of breast carcinoma in situ and is usually detected on mammography. DCIS can progress to invasive breast cancer if untreated.
Lobular carcinoma in situ (LCIS) — an abnormal change in the breast lobules. Classic LCIS is not itself considered cancer but is a marker of increased risk of developing invasive breast cancer in either breast. It is typically managed with surveillance rather than surgery.
Squamous cell carcinoma in situ (Bowen’s disease) — a non-invasive skin cancer in which the full thickness of the outer skin layer (epidermis) contains abnormal squamous cells. It appears as a slow-growing, red scaly patch and is highly curable with treatment.
High grade squamous intraepithelial lesion (HSIL) / cervical intraepithelial neoplasia (CIN3) — severely abnormal squamous cells covering the surface of the cervix. Strongly associated with high-risk HPV infection. Treated with removal of the affected area to prevent progression to invasive cervical cancer.
Urothelial carcinoma in situ (CIS) — a high-grade non-invasive cancer confined to the lining of the urinary tract, most commonly the bladder. Despite being in situ, urothelial CIS carries a significant risk of progression to invasive bladder cancer and is treated aggressively.
Adenocarcinoma in situ (AIS) — abnormal glandular cells confined to the epithelial surface of an organ. Most commonly diagnosed in the cervix and lung. See dedicated guides for AIS of the cervix and AIS of the lung.

What does a carcinoma in situ diagnosis mean?

A diagnosis of carcinoma in situ is serious enough to require treatment — these are genuine cancer cells — but it also carries an excellent outlook because the cells have not yet spread. The primary goal of treatment is to remove all abnormal tissue before invasion occurs. Your pathologist will carefully examine the surgical margins to determine whether the in situ lesion has been fully excised. A clear margin is reassuring; a positive or close margin may indicate the need for further treatment.

The risk of progression to invasive cancer varies by type and location. Urothelial CIS, for example, progresses to invasion relatively quickly without treatment, while classic LCIS of the breast may never progress in many patients. Your doctor will explain what your specific type of carcinoma in situ means for your follow-up and management.

Questions to ask your doctor

What type of carcinoma in situ was found, and in which organ?
Were the surgical margins clear, and was it completely removed?
What is the risk of progression to invasive cancer, and what monitoring or treatment is recommended?